Sexually transmitted infections in the era of antiretroviral-based HIV prevention: Priorities for discovery research, implementation science, and community involvement

English version České info

Jeanne M.
Marrazzo and colleagues join PLOS Medicine's Collection on the prevention, diagnosis, and treatment of STIs with a Perspective on HIV research imperatives in our time of effective viral suppression and pre-exposure prophylaxis.

Vyšlo v časopise: Sexually transmitted infections in the era of antiretroviral-based HIV prevention: Priorities for discovery research, implementation science, and community involvement. PLoS Med 15(1): e32767. doi:10.1371/journal.pmed.1002485
Kategorie: Perspective
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1002485

Souhrn

Zdroje

1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med. 2016;375(9):830–9. doi: 10.1056/NEJMoa1600693 27424812; PubMed Central PMCID: PMC5049503.

2. Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV Preexposure Prophylaxis Among Commercially Insured Persons-United States, 2010–2014. Clin Infect Dis. 2017;64(2):144–9. doi: 10.1093/cid/ciw701 27986691.

3. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2015. Atlanta, GA: U.S. Department of Health and Human Services; October 2017. 2017.

4. Chen YH, Snowden JM, McFarland W, Raymond HF. Pre-exposure Prophylaxis (PrEP) Use, Seroadaptation, and Sexual Behavior Among Men Who Have Sex with Men, San Francisco, 2004–2014. AIDS Behav. 2016;20(12):2791–7. doi: 10.1007/s10461-016-1357-2 26983951.

5. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60. doi: 10.1016/S0140-6736(15)00056-2 26364263; PubMed Central PMCID: PMC4700047.

6. Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. The lancet HIV. 2017;4(9):e402–e10. doi: 10.1016/S2352-3018(17)30089-9 28747274.

7. Mayer KH, Maloney KM, Levine K, King D, Grasso C, Krakower DS, et al. Sociodemographic and Clinical Factors Associated With Increasing Bacterial Sexually Transmitted Infection Diagnoses in Men Who Have Sex With Men Accessing Care at a Boston Community Health Center (2005–2015). Open forum infectious diseases. 2017;4(4):ofx214. doi: 10.1093/ofid/ofx214 29181421; PubMed Central PMCID: PMC5695616.

8. Jenness SM, Weiss KM, Goodreau SM, Gift T, Chesson H, Hoover KW, et al. Incidence of Gonorrhea and Chlamydia Following Human Immunodeficiency Virus Preexposure Prophylaxis Among Men Who Have Sex With Men: A Modeling Study. Clin Infect Dis. 2017;65(5):712–8. doi: 10.1093/cid/cix439 28505240.

9. Fingerhuth SM, Bonhoeffer S, Low N, Althaus CL. Antibiotic-Resistant Neisseria gonorrhoeae Spread Faster with More Treatment, Not More Sexual Partners. PLoS Pathog. 2016;12(5):e1005611. doi: 10.1371/journal.ppat.1005611 27196299; PubMed Central PMCID: PMC4872991.

10. Wu G, Swanson M, Talla A, Graham D, Strizki J, Gorman D, et al. HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal. JCI Insight. 2017;2(16). doi: 10.1172/jci.insight.92901 28814661; PubMed Central PMCID: PMC5621903.

11. Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, et al. On demand post-exposure prophylaxis with doxycycline for MSM enrolled in a PrEP trial. 2017 Nov. Conference on Retroviruses and Opportunistic Infections (CROI); Seattle, WA, 2017.

12. Public Health England, British Association for Sexual Health and HIV. Position Statement on Doxycycline as Post—Exposure Prophylaxis for Sexually Transmitted Infections. London: Public Health England; 2017.